United Therapeutics Corporation Reports Third Quarter 2015 Financial Results

Go back to United Therapeutics Corporation Reports Third Quarter 2015 Financial Results

Cowen Remains Bullish on United Therapeutics (UTHR) as Orenitram Continues to Grow

October 27, 2015 4:01 PM EDT

Cowen reiterated an Outperform rating and $185.00 price target on United Therapeutics Corp. (NASDAQ: UTHR) following the company's 3Q15 earnings results. All pulmonary hypertension products beat expectations, driving revenue and EPS above consensus.

Analyst Phil Nadeau commented, "UTHR reported strong Q3 results this morning. All pulmonary... More

Leerink Partners Reiterates Market Perform Following United Therapeutics (UTHR) 3Q beat

October 27, 2015 1:44 PM EDT

Leerink Partners reiterated a Market Perform rating and $166.00 price target on United Therapeutics Corp. (NASDAQ: UTHR) following the company's 3Q15 earnings report. UTHR reported 3Q revenues and non-GAAP EPS of $386M and $3.55 that beat Street estimates of $362M and $3.22. Management reported that sales... More

United Therapeutics (UTHR) Tops Q3 EPS by 120c

October 27, 2015 6:24 AM EDT

United Therapeutics (NASDAQ: UTHR) reported Q3 EPS of $3.55, $1.20 better than the analyst estimate of $2.35. Revenue for the quarter came in at $386.2 million versus the consensus estimate of $363.5 million.

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.

... More